Org, Elin, juhendajaKrigul, Kertu Liis, juhendajaKazimova, Valida2023-06-212023-06-212023https://hdl.handle.net/10062/90897Type 2 Diabetes (T2D) is a globally recognized health concern that has garnered significant research attention. This thesis work focuses on gut microbiome analysis in T2D patients who start taking two medications antidiabetic drugs: Empaglifrozin (SGLT2i) and Semaglutide (GLP1RA). Microbiome composition was analyzed using 16S rRNA sequencing. The research aims to enhance our understanding of how the gut microbiome is related to SGLT2/GLP1 drug intake, potentially leading to the development of personalized treatment approaches for improved patient outcomes.engopenAccessAttribution-NonCommercial-NoDerivatives 4.0 InternationalType 2 DiabetesSGLT2iGLP1RAgut microbiomeEmpaglifrozinSemaglutideThesis